RxDoctor Payments Data

John Meadows

Allergy · Birmingham, ALNPI 1811952849

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $143,250 of the $203,503 with a category attached, or 70.4%. 30 manufacturers reported payments, led by AstraZeneca at 26.6% of the total. Reporting peaked in 2022 at $62,748 and has fallen 98.7% since, to $838 in 2025.

$203,503in general payments, 2019–2025

Across 577 payments — averaging $352.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$54K
  • Teva Pharmaceuticals USA, Inc.$51K
  • Regeneron Healthcare Solutions, Inc.$23K
  • Sanofi$20K
  • Pfizer$20K
  • Takeda Pharmaceuticals U.S.A., Inc.$17K
  • plus $18K from 24 others

What the payments were for

  • Consulting fees$36,01918%
  • Speaking & faculty fees$143,25070%
  • Grants$5000%
  • Travel & lodging$11,9186%
  • Food & beverage$11,6866%
  • Education$1300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in Alabamato place this figure against a meaningful peer group, so we don't.

Other allergy in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →